In re HIV Antitrust Litigation
Case Number:
3:19-cv-02573
See also:
Court:
Nature of Suit:
Multi Party Litigation:
Class Action
Judge:
Firms
- Arnold & Porter
- Baron & Budd
- Berry Silberberg
- Boies Schiller
- Cahill Gordon
- Crowell & Moring
- Dillingham & Murphy
- Duane Morris
- Faegre Drinker
- Glancy Prongay
- Goodwin Procter
- Hagens Berman
- Hangley Aronchick
- Hausfeld LLP
- Hilliard & Shadowen
- Holland & Knight
- Kanner & Whiteley
- Kellogg Hansen
- Kenny Nachwalter
- Kessler Topaz
- Kirkland & Ellis
- Law Offices of Francis O. Scarpulla
- Lockridge Grindal
- Milberg Coleman
- Miller Shah LLP
- Morrison Foerster
- NastLaw
- Nixon Peabody
- Nussbaum Law Group
- Pritzker Levine
- Proskauer Rose
- Radice Law Firm
- Rivero Mestre
- Robins Kaplan
- Spector Roseman
- Sperling & Slater
- Whatley Kallas
- White & Case
- Wilson Sonsini
- Zelle LLP
Companies
- Aetna Inc.
- Akros Pharma Inc.
- Albertsons Cos. Inc.
- Amneal Pharmaceuticals Inc.
- Blue Cross Blue Shield Association
- BlueCross BlueShield of South Carolina
- Bristol-Myers Squibb Co.
- Centene Corp.
- Cipla Ltd.
- CVS Health Corp.
- Florida Blue
- Fraternal Order of Police
- Gilead Sciences Inc.
- Health Care Service Corp.
- Humana Inc.
- Japan Tobacco
- Johnson & Johnson
- LifeWallet
- Rite Aid Corp.
- Service Employees International Union
- Teva Pharmaceutical Industries Ltd.
- The Kroger Co.
- Zydus Pharmaceuticals Inc.
Government Agencies
Sectors & Industries:
-
April 19, 2023
Gilead, Janssen, Teva Can't Say HIV Drug Costs Passed On
Health care insurers going to trial next month in their suit against Gilead, Janssen and Teva won't have to worry about arguments they passed on any overcharges after a California federal judge banned the drugmakers from using that defense in the sprawling certified consumer antitrust class action alleging drugmakers artificially inflated HIV drug prices.
-
February 21, 2023
Gilead, Janssen And Teva Face HIV Drug Antitrust Trial In May
A California federal judge has unveiled his reasoning for mostly refusing to hand either side a clear-cut summary judgment victory in the sprawling certified consumer antitrust class action alleging that Gilead, Janssen and other drugmakers artificially inflated HIV drug prices, teeing up the high-stakes dispute for a May jury trial.
-
November 04, 2022
HIV Drug Buyers Win Cert. In Gilead, Janssen Antitrust Suit
A California federal judge granted class certification to end-payor plaintiffs and direct-purchaser plaintiffs in a suit accusing Gilead and Janssen of artificially inflating HIV drug prices by illegally staving off competition from cheaper generics, according to an order unsealed this week.
-
October 31, 2022
Direct HIV Med Buyers Seek OK Of $10.8M Bristol-Myers Deal
A putative class of direct HIV medication buyers asked a California federal judge to give final approval to a $10.8 million deal that would end claims that Bristol-Myers Squibb engaged in anti-competitive conduct to block generics competition and keep the medication's prices artificially high.
-
April 07, 2022
Gilead Says Aetna Must Litigate Its HIV Drug Suit In Fed Court
Gilead urged a California federal judge Thursday to reject Aetna's bid to send to state court its second lawsuit accusing Gilead and others of illegally driving up HIV drug prices by blocking generic versions, saying Aetna already dropped a similar suit and shouldn't be allowed to pursue this litigation "tactic."
-
March 29, 2022
Gilead Can't Force Aetna HIV Suit On Its Terms
A California federal judge refused Tuesday to let Gilead forcibly revive an Aetna lawsuit, which the insurer voluntarily dismissed, in order to avoid a state court fight alongside the array of federal antitrust lawsuits accusing the drugmaker and others of driving up HIV drug prices by illegally staving off cheaper generic versions.
-
March 16, 2022
BCBS Stays In Gilead HIV Suit As More Than An Intermediary
The Blue Cross Blue Shield Association has sufficiently demonstrated it belongs, for now, among end-payors accusing Gilead Sciences Inc. and Janssen Pharmaceuticals of driving up HIV drug prices by illegally staving off cheaper generic versions, according to a California federal judge.
-
March 08, 2022
UnitedHealth's HIV Drug Suit Against Teva, Gilead Trimmed
A California federal court on Tuesday trimmed several state law claims while keeping others intact in United Healthcare's suit alleging it overpaid for HIV drugs because Teva and Gilead delayed cheaper generic versions.
-
March 03, 2022
Gilead, Teva Look To Trim United Health's HIV Generics Suit
Teva and Gilead urged a California federal judge Thursday to trim some state claims from United Healthcare's suit alleging the pair overcharged for HIV drugs by delaying cheaper generic versions, saying that consumer protection laws in some states named in the complaint do not extend to corporations or insurance companies.
-
January 14, 2022
Judge Limits Tolling On Retailer Claims In HIV Generics Suit
A California federal judge has trimmed antitrust claims that retailers including Walgreens and CVS filed against Teva over alleged overcharges for HIV drugs, saying any claims stretching back more than four years from their lawsuits are time-barred.